Lenalidomide maintenance after stem-cell transplantation for multiple myeloma

The New England Journal of Medicine
Michel AttalIFM Investigators

Abstract

High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-ye...Continue Reading

References

May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Jan 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart BarlogieJohn C Crowley
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Aug 31, 2006·British Journal of Haematology·Bart BarlogieJohn Crowley
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SpencerNola Kennedy
Oct 25, 2011·Blood·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Studies Group
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker

❮ Previous
Next ❯

Citations

Nov 28, 2012·Annals of Hematology·Chor Sang ChimWai Ki Lee
Oct 23, 2013·Current Hematologic Malignancy Reports·Sergio Giralt, Guenther Koehne
Mar 5, 2013·International Journal of Hematology·Marta Chesi, P Leif Bergsagel
Mar 12, 2013·International Journal of Hematology·Reiko WatanabeMasahiro Kizaki
Oct 1, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Isabelle Vande Broek, Peter Jacobs
Feb 15, 2014·The Lancet Oncology·Guy Pratt
Jun 6, 2012·Nature Reviews. Clinical Oncology·S Vincent Rajkumar
Mar 27, 2013·Nature Reviews. Clinical Oncology·Lois B TravisAndrea K Ng
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J L Harousseau
Aug 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Working Group
Jan 8, 2013·Japanese Journal of Clinical Oncology·Kenshi Suzuki
Mar 21, 2013·Anti-cancer Drugs·Yandun ZouJinming Yu
Oct 20, 2012·Current Opinion in Oncology·Margarita Blanes, Javier de la Rubia
Oct 26, 2012·Advances in Hematology·Donna ReeceJohn Ashkenas
Dec 6, 2012·Experimental Hematology & Oncology·Tahir LatifSaad Z Usmani
Sep 8, 2012·Cancer Management and Research·Niels Wcj van de DonkKenneth C Anderson
Dec 4, 2012·Mediterranean Journal of Hematology and Infectious Diseases·P TosiG Visani
Feb 7, 2013·Oman Medical Journal·Khalil Al-Farsi
Nov 29, 2013·International Journal of Hematologic Oncology·Jagoda K Jasielec, Andrzej J Jakubowiak
Aug 25, 2012·Stem Cells International·Joel Sng, Thomas Lufkin
Jul 11, 2013·Future Oncology·Peter A Forsberg, Tomer M Mark
Nov 19, 2013·Journal of Comparative Effectiveness Research·Boris FreidlinEdward L Korn

❮ Previous
Next ❯

Related Concepts